FY2024 · ended Dec 31, 2024 · Revenue $183,000 · Filed Apr 15, 2026
Abpro Holdings, Inc. (ABPO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
$183,000
Net income
$-2.89M
+60.0% vs prior year
Operating cash flow (TTM)
$-6.59M
+10.5% vs year-ago TTM
Free cash flow
$-7.45M
EPS
$-1.30
+94.2% vs prior year
Dividend per share
None
Shares outstanding
5.90M
-88.7% vs prior year
Net cash
$-389,000
FY 2025
Operating margin
-5421.3%
FY 2024
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ABPO (OTC), ABPWW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1893219
- Former names
- Atlantic Coastal Acquisition Corp. II (until Nov 12, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | — | $183,000 |
| Operating income | -$8.5M | -$9.9M |
| Net income | -$2.9M | -$7.2M |
| Diluted EPS | -$1.30 | -$22.31 |
| Operating cash flow | -$6.0M | -$9.0M |
| Total assets | $1.1M | $4.7M |
| Total liabilities | — | $19.6M |
| Stockholders' equity | -$8.8M | -$15.5M |
| Cash and investments | $67,000 | $2.9M |
| Total debt | $456,000 | $696,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 1, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 25, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Listing notice
|
Jun 4, 2026 | May 28, 2026 |
| 10-Q | Quarterly report | May 20, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | May 1, 2026 | Dec 31, 2025 |
All 253 Abpro Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.